ArticleFrontiers in medicine2026
Disseminated herpes zoster in adults: a single-center retrospective study on clinical spectrum and risk factors for adverse outcomes.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Disseminated herpes zoster (DHZ) is defined by the involvement of more than two non-contiguous dermatomes or the presence of at least 20 lesions beyond the primary affected dermatome. The varicella-zoster virus (VZV) can lead to disseminated infection when the host's immune response is insufficient to halt cell-associated viremia. This study aimed to summarize the clinical characteristics and potential risk factors associated with DHZ and to identify and assess factors related to prognosis to enhance the prevention and management strategies for DHZ patients. Methods: The demographic information of DHZ patients who presented to our department between January 2019 and January 2025 was retrospectively collected. Patients with a confirmed diagnosis of DHZ were monitored to identify morbidity risk factors and the incidence of postherpetic neuralgia. Results: A total of 109 patients were diagnosed with DHZ, with a male predominance (65 patients, 59.63%) and 44 female patients (40.37%). The mean age of the patients was 68.6 years. Advanced age (≥65 years) was the most prevalent demographic risk factor. In the assessment of prognostic outcomes, concomitant conditions including hypertension, diabetes, and cancer, along with severe pain (VAS score 7-10), were significantly associated with an increased risk of postherpetic neuralgia in a univariate analysis. Furthermore, a multivariable logistic regression analysis identified cancer as an independent risk factor for prolonged disease duration (OR = 4.271, Conclusion: This study identified advanced age, cardiovascular disease, and chronic inflammation as independent risk factors for DHZ, highlighting potential target groups for vaccination. Moreover, factors such as hypertension, diabetes, and severe initial pain were associated with postherpetic neuralgia (PHN) in a univariate analysis, suggesting avenues for early attention. These findings highlight the importance of early recognition, aggressive management, and, most importantly, targeted preventive vaccination with the non-live recombinant vaccine in high-risk populations, including cancer patients, to reduce the substantial morbidity associated with disseminated herpes zoster.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.